En Es
Categories

Industry News

AI-Based ICU Solution for Predicting Patient Deterioration Becomes Industry’s First Ever Device to Receive FDA Clearance

By HospiMedica International staff writers
09 Feb 2021

IllustrationA new artificial intelligence (AI) based ICU solution for predicting the likelihood of patient deterioration up to eight hours in advance has become the industry’s first ever device to receive clearance from the US Food and Drug Administration (FDA).

The FDA has given 510(k) clearance and authorized the use of “CLEWICU,” an AI-based ICU solution from CLEW Medical (Netanya, Israel), to predict hemodynamic instability in adult patients. The clearance is the FDA’s first for such a device, and follows the FDA’s Emergency Use Authorization (EUA) for the company’s respiratory deterioration model granted in June 2020, for the predictive screening of COVID-19 and other ICU patients.

The COVID-19 pandemic has underscored the critical need for quick and accurate decision-making in intensive care units, as ICU capacity has faced unprecedented volumes. Conducting effective risk evaluation to improve patient identification and subsequent care plans requires the use of advanced tools that can provide comprehensive, predictive data to help medical professionals identify patients whose health conditions are likely to deteriorate, in addition to patients whose conditions are unlikely to deteriorate.

CLEWICU continuously monitors and categorizes patient risk levels, providing clinicians with physiological insight into a patient’s likelihood of future hemodynamic instability. The system provides notification of clinical deterioration up to eight hours in advance, enabling early evaluation and subsequent intervention for prompt, proactive patient care. The system also identifies low-risk patients who are unlikely to deteriorate, thus enabling better ICU resource management and optimization.

The analytical software product uses AI-based algorithms and machine-learning models trained to identify the likelihood of occurrence of significant clinical events for patients in the ICU. CLEWICU receives patient data from various sources, including Electronic Health Record (EHR) data and medical device data. The data is analyzed in near real-time to present calculated insights and notifications for dedicated AI models and provides a picture of overall unit status.

“We are proud to have received this landmark FDA clearance and deliver a first-of-its-kind product for the industry, giving healthcare providers the critical data that they need to prevent life-threatening situations,” said Gal Salomon, CLEW CEO.

“AI can be a powerful force for change in healthcare, enabling assessment of time-critical patient information and predictive warning of deterioration that could enable better informed clinical decisions and improved outcomes in the ICU,” said Dr. David Bates, Medical Director of Clinical and Quality Analysis in Information Systems at Mass General Brigham healthcare system and CLEW Advisory Board member.

“CLEW’s AI-based solution is a huge leap forward in ICU patient care, providing preemptive and potentially life-saving information that enables early intervention, reduces alarm fatigue and can potentially significantly improve clinical outcomes,” stated Professor Craig Lilly, University of Massachusetts Medical School.

Related Links:
CLEW Medical



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

04 Mar 2021
Siemens Partners with Epsilon Imaging on EchoInsight Analysis Software with Strain Imaging
Siemens Healthineers (Erlangen, Germany) has entered into a partnership with Epsilon Imaging (Ann Arbor, MI, USA) to offer syngo Dynamics users EchoInsight visualization and analysis with strain imaging.
Read More
04 Mar 2021
Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis
Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell analysis and further explore AI technology in vitro diagnostics.
Read More
02 Mar 2021
Hologic Acquires European Molecular Diagnostic Company Diagenode
Hologic, Inc. (Marlborough, MA, USA) has acquired Diagenode (Liège, Belgium), a developer and manufacturer of molecular diagnostic assays and epigenetics products, which is expected to diversify its diagnostic business across test menu, customer segments and geography.
Read More
23 Feb 2021
AI-Guided Imaging Software Allows Nurses without Prior Ultrasound Experience to Capture Diagnostic Quality Images
A new study has demonstrated that ultrasound images captured by nurses using FDA-approved AI-guided medical imaging acquisition software without prior ultrasound experience and reviewed by experienced cardiologists were of diagnostic quality.
Read More
12 Feb 2021
Machine Learning Algorithm Identifies Deteriorating Patients in Hospital Who Need Intensive Care
Researchers have developed a machine learning algorithm that could significantly improve clinicians’ ability to identify hospitalized patients whose condition is deteriorating to the extent that they need intensive care.
Read More
05 Feb 2021
AI-Powered Artefact Removal Can Identify Poor-Quality MRI Images with Near-Human Accuracy in Milliseconds
A new study has demonstrated the effective use of a retrospective artefact correction (RAC) neural network learned with unpaired data to disentangle and remove unwanted artefacts in magnetic resonance (MR) images.
Read More
05 Feb 2021
Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents
Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products, including a multi-year extension.
Read More
04 Feb 2021
Hologic Partners with Google Cloud to Focus on AI and Machine Learning for Advancing Digital Diagnostic Capabilities
Hologic, Inc. (Marlborough, MA, USA) and Google Cloud have entered into a new agreement to focus on enhancing artificial intelligence (AI) and machine learning (ML) to bring about breakthrough results in cervical cancer screening.
Read More
03 Feb 2021
LGC Acquires Technopath Clinical Diagnostics to Strengthen Position in Clinical Diagnostics QC Market
 LGC (Middlesex, UK) has acquired Technopath Clinical Diagnostics (Tipperary, Ireland), a developer and manufacturer of quality control (QC) solutions for clinical laboratories.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions